AKT1 and prostate cancer: Since M-CSF mediates osteoclast differentiation via its receptor FMS and subsequent AKT activation, TAS-115 leads to a reduced NFKB-mediated osteoclast formation and, thus, prostate cancer-induced bone resorption in a xenograft mouse model [137].